안과 질환 치료제 시장 규모, 점유율, 성장률 및 업계 분석 : 유형 및 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of ophthalmic disease therapeutics Market

The global ophthalmic disease therapeutics market is witnessing steady growth driven by the increasing prevalence of eye-related disorders and rising demand for advanced treatment solutions. The market was valued at USD 40.09 billion in 2025 and is expected to grow to USD 42.61 billion in 2026, reaching USD 71.58 billion by 2034. This growth reflects continuous advancements in ophthalmic drug development and increasing awareness regarding eye health worldwide.

Ophthalmic therapeutics include drugs and treatments designed to manage conditions such as glaucoma, dry eye disease, retinal disorders, and ocular infections. The rising burden of these diseases, especially among the aging population, is significantly contributing to the expansion of the market.

Market Trends

A key trend shaping the market is the growing focus on advanced drug delivery systems. Traditional eye treatments often face limitations due to poor drug absorption and rapid elimination. To overcome these challenges, companies are investing in innovative solutions such as nanotechnology-based formulations, sustained-release implants, and drug-eluting contact lenses.

Additionally, the adoption of gene therapies and biologics is increasing. These advanced therapies offer targeted treatment options, improving patient outcomes and reducing the frequency of administration. The integration of artificial intelligence in diagnosis and treatment planning is also supporting the market's evolution.

Market Growth Drivers

The primary factor driving the ophthalmic disease therapeutics market is the rising prevalence of eye disorders. Conditions such as glaucoma and macular degeneration are becoming more common due to aging populations and lifestyle changes. Increasing screen time and environmental factors further contribute to vision-related problems.

Another major driver is the growing investment in research and development. Pharmaceutical companies are actively developing novel drugs and therapies to address unmet medical needs. The increasing number of clinical trials and regulatory approvals is accelerating product launches and expanding treatment options.

Moreover, rising healthcare expenditure and improved access to eye care services are boosting diagnosis and treatment rates globally, further supporting market growth.

Restraining Factors

Despite strong growth prospects, the market faces certain challenges. The high cost of biologics and advanced therapies remains a significant barrier, particularly in developing regions. Many patients struggle with affordability, leading to lower treatment adherence.

Additionally, lack of awareness and limited access to healthcare infrastructure in emerging economies restricts early diagnosis and treatment. These factors create a gap between the patient population and available therapeutic solutions, slowing overall market adoption.

Segmentation Analysis

By Drug Class

The market is segmented into anti-inflammatory, anti-infectives, anti-VEGF, anti-glaucoma, and others. The anti-inflammatory segment holds a significant share in 2026, driven by high demand for treatments addressing ocular inflammation and allergies. Meanwhile, anti-VEGF therapies are expected to grow rapidly due to increasing cases of retinal diseases.

By Dosage Form

Based on dosage form, the market includes liquid, solid, and semisolid formulations. The semisolid segment dominates with 79.59% share in 2026, owing to its prolonged drug retention and effectiveness. Liquid forms remain widely used due to ease of administration.

By Disease Indication

Retinal diseases lead the segment with a 33.94% market share in 2026, driven by rising cases of diabetic retinopathy and macular degeneration. Dry eye disease and glaucoma segments are also expanding steadily.

By Distribution Channel

Retail and online pharmacies dominate the market with 89.97% share in 2026, supported by increasing digital adoption and convenience in purchasing medications.

Regional Insights

North America holds the largest share, accounting for 43.37% in 2025, with a market value of USD 17.39 billion, rising to USD 18.48 billion in 2026. The region benefits from strong healthcare infrastructure, high awareness, and continuous product approvals.

Europe follows as the second-largest market, driven by an aging population and increasing prevalence of eye diseases. Asia Pacific is expected to witness the fastest growth due to rising healthcare investments and growing patient awareness.

Latin America and the Middle East & Africa are gradually expanding, supported by improving healthcare access and increasing adoption of advanced therapies.

Conclusion

The ophthalmic disease therapeutics market is set for robust growth from USD 40.09 billion in 2025 to USD 71.58 billion by 2034, driven by rising prevalence of eye disorders, technological advancements, and increasing R&D activities. While high treatment costs and limited awareness in emerging regions pose challenges, ongoing innovations and expanding healthcare access are expected to bridge these gaps. Overall, the market presents significant opportunities for stakeholders, with continuous advancements shaping the future of eye care globally.

Segmentation By Drug Class

• Anti-inflammatory
• Anti-infectives
• Anti-VEGF
• Anti-glaucoma
  • Beta Blockers
  • Prostaglandins Analogs
  • Alpha Adrenergic Agonists
  • Carbonic Anhydrase Inhibitors
  • Combination Drugs
  • Others
• Others

By Dosage Form

• Solid
• Liquid
• Semisolid

By Disease Indication

• Glaucoma
  • Open Angle Glaucoma
  • Angle Closure Glaucoma
  • Others
• Dry Eye Disease
• Retinal Diseases
  • Diabetic Macular Edema (DME)
  • Macular Degeneration (AMD)
  • Diabetic Retinopathy (DR)
  • Retinal Vein Occlusion (RVO)
  • Others
• Allergy & Infections
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail & Online Pharmacies

By Region

• North America (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country)
  • U.S.
  • Canada
• Europe (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Major Ophthalmic Diseases, in Key Countries/ Region, 2025
• 4.2. Pipeline Analysis, By Key Players
• 4.3. Patent Snapshot, By Key Players
• 4.4. Key Industry Developments - Merges, Acquisitions and Partnerships
• 4.5. Regulatory Scenario for Key Countries
• 4.6. Reimbursement Scenario for Key Countries
• 4.7. Impact of COVID-19 on the Market

5. Global Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Class
  • 5.1.1. Anti-inflammatory
  • 5.1.2. Anti-infectives
  • 5.1.3. Anti-VEGF
  • 5.1.4. Anti-glaucoma
    • 5.1.4.1. Beta Blockers
    • 5.1.4.2. Prostaglandins Analogs
    • 5.1.4.3. Alpha Adrenergic Agonists
    • 5.1.4.4. Carbonic Anhydrase Inhibitors
    • 5.1.4.5. Combination Drugs
    • 5.1.4.6. Others
  • 5.1.5. Others
• 5.2. Market Analysis, Insights and Forecast - By Dosage Form
  • 5.2.1. Solid
  • 5.2.2. Liquid
  • 5.2.3. Semisolid
• 5.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 5.3.1. Glaucoma
    • 5.3.1.1. Open Angle Glaucoma
    • 5.3.1.2. Angle Closure Glaucoma
    • 5.3.1.3. Others
  • 5.3.2. Dry Eye Disease
  • 5.3.3. Retinal Diseases
    • 5.3.3.1. Diabetic Macular Edema (DME)
    • 5.3.3.2. Macular Degeneration (AMD)
    • 5.3.3.3. Diabetic Retinopathy (DR)
    • 5.3.3.4. Retinal Vein Occlusion (RVO)
    • 5.3.3.5. Others
  • 5.3.4. Allergy & Infections
  • 5.3.5. Others
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacies
  • 5.4.2. Retail & Online Pharmacies
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Class
  • 6.1.1. Anti-inflammatory
  • 6.1.2. Anti-infectives
  • 6.1.3. Anti-VEGF
  • 6.1.4. Anti-glaucoma
    • 6.1.4.1. Beta Blockers
    • 6.1.4.2. Prostaglandins Analogs
    • 6.1.4.3. Alpha Adrenergic Agonists
    • 6.1.4.4. Carbonic Anhydrase Inhibitors
    • 6.1.4.5. Combination Drugs
    • 6.1.4.6. Others
  • 6.1.5. Others
• 6.2. Market Analysis, Insights and Forecast - By Dosage Form
  • 6.2.1. Solid
  • 6.2.2. Liquid
  • 6.2.3. Semisolid
• 6.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 6.3.1. Glaucoma
    • 6.3.1.1. Open Angle Glaucoma
    • 6.3.1.2. Angle Closure Glaucoma
    • 6.3.1.3. Others
  • 6.3.2. Dry Eye Disease
  • 6.3.3. Retinal Diseases
    • 6.3.3.1. Diabetic Macular Edema (DME)
    • 6.3.3.2. Macular Degeneration (AMD)
    • 6.3.3.3. Diabetic Retinopathy (DR)
    • 6.3.3.4. Retinal Vein Occlusion (RVO)
    • 6.3.3.5. Others
  • 6.3.4. Allergy & Infections
  • 6.3.5. Others
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital Pharmacies
  • 6.4.2. Retail & Online Pharmacies
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Class
  • 7.1.1. Anti-inflammatory
  • 7.1.2. Anti-infectives
  • 7.1.3. Anti-VEGF
  • 7.1.4. Anti-glaucoma
    • 7.1.4.1. Beta Blockers
    • 7.1.4.2. Prostaglandins Analogs
    • 7.1.4.3. Alpha Adrenergic Agonists
    • 7.1.4.4. Carbonic Anhydrase Inhibitors
    • 7.1.4.5. Combination Drugs
    • 7.1.4.6. Others
  • 7.1.5. Others
• 7.2. Market Analysis, Insights and Forecast - By Dosage Form
  • 7.2.1. Solid
  • 7.2.2. Liquid
  • 7.2.3. Semisolid
• 7.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 7.3.1. Glaucoma
    • 7.3.1.1. Open Angle Glaucoma
    • 7.3.1.2. Angle Closure Glaucoma
    • 7.3.1.3. Others
  • 7.3.2. Dry Eye Disease
  • 7.3.3. Retinal Diseases
    • 7.3.3.1. Diabetic Macular Edema (DME)
    • 7.3.3.2. Macular Degeneration (AMD)
    • 7.3.3.3. Diabetic Retinopathy (DR)
    • 7.3.3.4. Retinal Vein Occlusion (RVO)
    • 7.3.3.5. Others
  • 7.3.4. Allergy & Infections
  • 7.3.5. Others
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital Pharmacies
  • 7.4.2. Retail & Online Pharmacies
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.5.1. U.K
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Class
  • 8.1.1. Anti-inflammatory
  • 8.1.2. Anti-infectives
  • 8.1.3. Anti-VEGF
  • 8.1.4. Anti-glaucoma
    • 8.1.4.1. Beta Blockers
    • 8.1.4.2. Prostaglandins Analogs
    • 8.1.4.3. Alpha Adrenergic Agonists
    • 8.1.4.4. Carbonic Anhydrase Inhibitors
    • 8.1.4.5. Combination Drugs
    • 8.1.4.6. Others
  • 8.1.5. Others
• 8.2. Market Analysis, Insights and Forecast - By Dosage Form
  • 8.2.1. Solid
  • 8.2.2. Liquid
  • 8.2.3. Semisolid
• 8.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 8.3.1. Glaucoma
    • 8.3.1.1. Open Angle Glaucoma
    • 8.3.1.2. Angle Closure Glaucoma
    • 8.3.1.3. Others
  • 8.3.2. Dry Eye Disease
  • 8.3.3. Retinal Diseases
    • 8.3.3.1. Diabetic Macular Edema (DME)
    • 8.3.3.2. Macular Degeneration (AMD)
    • 8.3.3.3. Diabetic Retinopathy (DR)
    • 8.3.3.4. Retinal Vein Occlusion (RVO)
    • 8.3.3.5. Others
  • 8.3.4. Allergy & Infections
  • 8.3.5. Others
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital Pharmacies
  • 8.4.2. Retail & Online Pharmacies
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Class
  • 9.1.1. Anti-inflammatory
  • 9.1.2. Anti-infectives
  • 9.1.3. Anti-VEGF
  • 9.1.4. Anti-glaucoma
    • 9.1.4.1. Beta Blockers
    • 9.1.4.2. Prostaglandins Analogs
    • 9.1.4.3. Alpha Adrenergic Agonists
    • 9.1.4.4. Carbonic Anhydrase Inhibitors
    • 9.1.4.5. Combination Drugs
    • 9.1.4.6. Others
  • 9.1.5. Others
• 9.2. Market Analysis, Insights and Forecast - By Dosage Form
  • 9.2.1. Solid
  • 9.2.2. Liquid
  • 9.2.3. Semisolid
• 9.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 9.3.1. Glaucoma
    • 9.3.1.1. Open Angle Glaucoma
    • 9.3.1.2. Angle Closure Glaucoma
    • 9.3.1.3. Others
  • 9.3.2. Dry Eye Disease
  • 9.3.3. Retinal Diseases
    • 9.3.3.1. Diabetic Macular Edema (DME)
    • 9.3.3.2. Macular Degeneration (AMD)
    • 9.3.3.3. Diabetic Retinopathy (DR)
    • 9.3.3.4. Retinal Vein Occlusion (RVO)
    • 9.3.3.5. Others
  • 9.3.4. Allergy & Infections
  • 9.3.5. Others
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital Pharmacies
  • 9.4.2. Retail & Online Pharmacies
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug Class
  • 10.1.1. Anti-inflammatory
  • 10.1.2. Anti-infectives
  • 10.1.3. Anti-VEGF
  • 10.1.4. Anti-glaucoma
    • 10.1.4.1. Beta Blockers
    • 10.1.4.2. Prostaglandins Analogs
    • 10.1.4.3. Alpha Adrenergic Agonists
    • 10.1.4.4. Carbonic Anhydrase Inhibitors
    • 10.1.4.5. Combination Drugs
    • 10.1.4.6. Others
  • 10.1.5. Others
• 10.2. Market Analysis, Insights and Forecast - By Dosage Form
  • 10.2.1. Solid
  • 10.2.2. Liquid
  • 10.2.3. Semisolid
• 10.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 10.3.1. Glaucoma
    • 10.3.1.1. Open Angle Glaucoma
    • 10.3.1.2. Angle Closure Glaucoma
    • 10.3.1.3. Others
  • 10.3.2. Dry Eye Disease
  • 10.3.3. Retinal Diseases
    • 10.3.3.1. Diabetic Macular Edema (DME)
    • 10.3.3.2. Macular Degeneration (AMD)
    • 10.3.3.3. Diabetic Retinopathy (DR)
    • 10.3.3.4. Retinal Vein Occlusion (RVO)
    • 10.3.3.5. Others
  • 10.3.4. Allergy & Infections
  • 10.3.5. Others
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospital Pharmacies
  • 10.4.2. Retail & Online Pharmacies
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Viatris Inc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Novartis AG
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. AbbVie Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. F. Hoffmann-La Roche Ltd.
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Regeneron Pharmaceuticals, Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Santen Pharmaceutical Co., Ltd.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Bayer AG
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Bausch & Lomb Incorporated
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Merck KGaA
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & Services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)